Analysts Set Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Target Price at $22.75

Posted by George Bondi on Jun 22nd, 2026

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL – Get Free Report) has received an average rating of “Hold” from the five research firms that are covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $17.1667.

Several analysts have recently commented on ADIL shares. Needham & Company LLC lowered shares of Adial Pharmaceuticals to a “buy” rating in a research report on Monday, June 15th. Brookline Capital Markets lowered shares of Adial Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, June 11th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Adial Pharmaceuticals in a research report on Monday, April 20th. Finally, Loop Capital set a $6.00 price target on shares of Adial Pharmaceuticals in a research report on Monday, June 15th.

Check Out Our Latest Report on ADIL

Adial Pharmaceuticals Price Performance

ADIL stock opened at $2.60 on Monday. The company’s 50 day simple moving average is $1.96 and its 200-day simple moving average is $3.42. The firm has a market capitalization of $5.56 million, a PE ratio of -0.33 and a beta of 1.46. Adial Pharmaceuticals has a 12 month low of $1.31 and a 12 month high of $18.90.

Adial Pharmaceuticals (NASDAQ:ADIL – Get Free Report) last released its quarterly earnings results on Friday, May 8th. The company reported ($1.48) EPS for the quarter, beating the consensus estimate of ($2.73) by $1.25.

Hedge Funds Weigh In On Adial Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the company. Armistice Capital LLC purchased a new position in shares of Adial Pharmaceuticals during the fourth quarter valued at approximately $562,000. Citadel Advisors LLC purchased a new position in shares of Adial Pharmaceuticals during the third quarter valued at approximately $51,000. Finally, Jane Street Group LLC lifted its stake in shares of Adial Pharmaceuticals by 887.3% during the fourth quarter. Jane Street Group LLC now owns 121,841 shares of the company’s stock valued at $27,000 after buying an additional 109,500 shares during the period. Hedge funds and other institutional investors own 16.41% of the company’s stock.

About Adial Pharmaceuticals

(Get Free Report)

Adial Pharmaceuticals, Inc, incorporated in Delaware and founded in 2003, is a clinical-stage specialty pharmaceutical company dedicated to the development of treatments for addiction disorders and central nervous system conditions. The company’s mission centers on creating novel modalities designed to enhance patient adherence and clinical outcomes, particularly in areas of high unmet medical need. Adial leverages sustained-release delivery technologies to address the challenges associated with oral medication regimens in addiction therapy.

The company’s lead product candidate, AD04, is a bioerodible subcutaneous implant engineered to deliver naltrexone continuously over a multi-month period for individuals with alcohol dependence.